Literature DB >> 32312774

Thioridazine Is an Efflux Pump Inhibitor in Mycobacterium avium Complex but of Limited Clinical Relevance.

Mike Marvin Ruth1, Lian J Pennings1, Valerie A C M Koeken2, Jodie A Schildkraut1, Aria Hashemi1, Heiman F L Wertheim1, Wouter Hoefsloot3, Jakko van Ingen4.   

Abstract

Treatment of Mycobacterium avium complex pulmonary disease (MAC-PD) is challenging partly due to high efflux pump expression. Thioridazine might block these efflux pumps. We explore the efficacy of thioridazine against M. avium isolates using MICs, time-kill combination assays, ex vivo macrophage infection assays, and efflux assays. Thioridazine is bactericidal against M. avium, inhibits intracellular growth at 2× MIC, and blocks ethidium bromide efflux. However, its toxicity and low plasma concentrations make it unlikely to add efficacy to MAC-PD therapy.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  M. avium; efflux pumps; thioridazine

Mesh：

Substances：

Year:  2020        PMID： 32312774      PMCID： PMC7318027          DOI： 10.1128/AAC.00181-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  22 in total

1.  Synergy, antagonism, and what the chequerboard puts between them.

Authors:  F C Odds
Journal:  J Antimicrob Chemother       Date:  2003-06-12       Impact factor: 5.790

Review 2.  Drug treatment of pulmonary nontuberculous mycobacterial disease in HIV-negative patients: the evidence.

Authors:  Jakko van Ingen; Beatriz E Ferro; Wouter Hoefsloot; Martin J Boeree; Dick van Soolingen
Journal:  Expert Rev Anti Infect Ther       Date:  2013-10       Impact factor: 5.091

3.  Measuring efflux and permeability in mycobacteria.

Authors:  Liliana Rodrigues; Miguel Viveiros; José A Aínsa
Journal:  Methods Mol Biol       Date:  2015

4.  Minocycline treatment for pulmonary Mycobacterium avium complex disease based on pharmacokinetics/pharmacodynamics and Bayesian framework mathematical models.

Authors:  Mike M Ruth; Gesham Magombedze; Tawanda Gumbo; Paula Bendet; Jasper J N Sangen; Sanne Zweijpfenning; Wouter Hoefsloot; Lian Pennings; Valerie A C M Koeken; Heiman F L Wertheim; Pooi S Lee; Jakko van Ingen; Devyani Deshpande
Journal:  J Antimicrob Chemother       Date:  2019-07-01       Impact factor: 5.790

5.  Concentration-related pharmacodynamic effects of thioridazine and its metabolites in humans.

Authors:  K Hartigan-Go; D N Bateman; G Nyberg; E Mårtensson; S H Thomas
Journal:  Clin Pharmacol Ther       Date:  1996-11       Impact factor: 6.875

6.  Enhancement of antibiotic activity against poly-drug resistant Mycobacterium tuberculosis by phenothiazines.

Authors:  M Viveiros; L Amaral
Journal:  Int J Antimicrob Agents       Date:  2001-03       Impact factor: 5.283

Review 7.  Thioridazine: resurrection as an antimicrobial agent?

Authors:  H K R Thanacoody
Journal:  Br J Clin Pharmacol       Date:  2007-08-31       Impact factor: 4.335

8.  Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.

Authors:  Carina Beatrice Vibe; Federico Fenaroli; David Pires; Steven Ray Wilson; Vanya Bogoeva; Raja Kalluru; Martin Speth; Elsa Anes; Gareth Griffiths; Jon Hildahl
Journal:  Nanotoxicology       Date:  2015-11-17       Impact factor: 5.913

9.  Thioridazine and chlorpromazine inhibition of ethidium bromide efflux in Mycobacterium avium and Mycobacterium smegmatis.

Authors:  Liliana Rodrigues; Dirk Wagner; Miguel Viveiros; Daniela Sampaio; Isabel Couto; Martina Vavra; Winfried V Kern; Leonard Amaral
Journal:  J Antimicrob Chemother       Date:  2008-02-29       Impact factor: 5.790

10.  Thioridazine as Chemotherapy for Mycobacterium avium Complex Diseases.

Authors:  Devyani Deshpande; Shashikant Srivastava; Sandirai Musuka; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191
View more
  3 in total

1.  Cupressus sempervirens Essential Oil: Exploring the Antibacterial Multitarget Mechanisms, Chemcomputational Toxicity Prediction, and Safety Assessment in Zebrafish Embryos.

Authors:  Sarra Akermi; Slim Smaoui; Khaoula Elhadef; Mariam Fourati; Nacim Louhichi; Moufida Chaari; Ahlem Chakchouk Mtibaa; Aissette Baanannou; Saber Masmoudi; Lotfi Mellouli
Journal:  Molecules       Date:  2022-04-19       Impact factor: 4.927

Review 2.  The New Frontier of Host-Directed Therapies for Mycobacterium avium Complex.

Authors:  Nathan P Crilly; Samuel K Ayeh; Petros C Karakousis
Journal:  Front Immunol       Date:  2021-01-22       Impact factor: 7.561

Review 3.  Non-Antibiotic Drug Repositioning as an Alternative Antimicrobial Approach.

Authors:  Alexia Barbarossa; Antonio Rosato; Filomena Corbo; Maria Lisa Clodoveo; Giuseppe Fracchiolla; Antonio Carrieri; Alessia Carocci
Journal:  Antibiotics (Basel)       Date:  2022-06-17
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.